TriSalus Life Sciences, Inc. (TLSI)
Oxford Ledge is still expanding full research coverage of TLSI. A delayed quote, fundamentals, and analysis are available in the app; the SEC-sourced material below is what we currently have indexed here.
Business summary
The company develops medical devices through partnerships and customer relationships but faces risks from contract termination, employee retention, and competition for talent.
Source: 10-K (2025-12-31) · AI-generated analysis. Not investment advice. May contain errors.
SEC filings
- 8-K Shareholder vote results 2026-05-14
- 10-Q Quarterly financial report (unaudited) 2026-05-12
- 8-K Results of operations / financial condition; Financial statements and exhibits 2026-05-12
- 8-K Departure/election of directors or officers 2026-04-29
- 8-K Departure/election of directors or officers; Regulation FD disclosure; Financial statements and exhibits 2026-04-07
Source: SEC EDGAR.
Annual results
5 years of annual figures for TLSI, as filed with the SEC. Figures are as reported and are not restated or adjusted.
| Fiscal year | Revenue | Net income | EPS (diluted) |
|---|---|---|---|
| 2025 | $45.2M | -$39.2M | -$1.84 |
| 2024 | $29.4M | -$30.0M | -$1.31 |
| 2023 | $18.5M | -$59.4M | -$6.77 |
| 2022 | $12.4M | -$47.2M | -$161.55 |
| 2021 | — | $4.8M | — |
Source: SEC EDGAR (XBRL company facts). Full statements and ratios in the terminal.
Insider activity
5 recent insider (SEC Form 4) filings on record for TLSI. View the transactions in the terminal.
Source: SEC EDGAR (Form 4).
- Open TLSI in the Oxford Ledge terminal — delayed quote, chart, and analysis in the app.
- Browse the covered-stock index
- Learn to analyze stocks yourself
The material above is drawn from public SEC EDGAR filings and is provided for educational purposes, not as investment advice. Live pricing and fundamentals are available in the terminal.